Klotho (KLTO.US) gene therapy has the potential to reverse organ degeneration, with the stock price skyrocketing by 787% in a single day.

Klotho Neurosciences (KLTO.US) announced early research results showing that Klotho's innovative gene therapy may be able to completely reverse age-related organ degeneration. The company's stock price surged by 787% on the US stock market, and this exaggerated increase was sustained until the market closed, triggering a "biotech trading frenzy" in the US stock market and attracting global funds to invest in the stock. The narrative of anti-aging genes and longevity economy has been a hot topic in the global secondary market in recent years, with investor sentiment highly sensitive to any "longevity" signals. The preclinical trials of Klotho Neurosciences have shown that increasing Klotho gene expression can slow down the process of organ degeneration with age. Thanks to this positive news, by the time the US market closed, the stock price had soared by as much as 787%, with trading volume exceeding 1.1 billion shares, far beyond the usual levels. At the same time, Synaptogenix (SNPX.US) entered the cryptocurrency field by investing $10 million in the "tao" cryptocurrency focused on AI big models, and by Monday's closing, the stock price had risen by over 44%. These moves highlight how innovation is reshaping market dynamics. The single-day skyrocketing stock price of Klotho Neurosciences shows that cutting-edge biotech research can quickly ignite investment enthusiasm and increase trading volume. As Synaptogenix announces its foray into cryptocurrencies and AI, the market is closely watching technological changes and may recalibrate investment focus. Investors who want to grasp the trends in cutting-edge technology need to weigh the investment risks and opportunities in a fast-paced innovation environment. The progress of Klotho Neurosciences also reflects a broader trend in biotech - exploring the use of gene therapy to combat degenerative diseases. Such technological leaps will not only profoundly impact the global medical development pace but also reshape market and regulatory dynamics. With innovation speeding up, the intersection of cutting-edge biotech and investment strategies has become a major focus for global market participants. Information shows that Klotho Neurosciences is a US micro-biotech company focusing on "anti-aging" and gene therapy for neurodegenerative diseases. The reason why the stock price skyrocketed by over 780% yesterday lies in the company's announcement of the latest animal experiment data on -Klotho gene therapy, showing its potential to delay, and even reverse, multi-organ aging. This instantly ignited the market's fervent pursuit of the concept of "small-cap anti-aging", and due to the influx of global funds, the limited floating stock and increased turnover amplified the price fluctuations. Klotho stated that in various animal models, delivery of the s-Klotho gene through AAV can significantly improve heart, liver, kidney, and brain function indicators, and show signs of longevity extension. The company's latest announcement emphasizes that they have obtained global exclusive patent licenses and plan to apply for a Pre-IND meeting with the FDA. The core technology of Klotho Neurosciences lies in the development of a disposable or low-frequency dosing in vivo gene therapy using a patented secretable -Klotho (s-KL) gene delivery vector to slow down the degenerative nature of the central nervous system and multi-organ with age. The product pipeline mainly includes AAV-Klotho gene therapy treatment for Alzheimer's disease, Parkinson's disease, ALS (pre-clinical stage), and exogenous recombinant s-KL protein supplementation therapy (pre-clinical stage). Klotho Neurosciences attracted global speculative capital and quantitative trading by releasing eye-catching early results of longevity/anti-aging gene therapy, combined with the characteristics of an extremely small market cap. However, for investors in the biotech theme, the risks of investing in Klotho are that current data is limited to animal experiments, human trials and commercialization are still far away, and the success rate, regulatory pathway, and funding requirements are highly uncertain; in addition, the company's financial fundamentals are very fragile, with limited cash on hand, no revenue, and the need for multiple rounds of financing that may lead to dilution.